United States · Markets & Finance · Reuters Business

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

Published by Reuters Business · United States 13 h ago

Australia's CSL said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to ‌co-develop and co-promote a treatment for rare kidney and liver…

Read the full article on Reuters Business Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.reuters.com)

Also worth reading

CNBC

They survived World War II and lost decades, but not 2026. Japan's century-old businesses are disappearing at a record pace

Cointelegraph

Zcash gets a Washington lobbyist to push crypto policy

Fortune

Air Force removes all bombers from British base and redeploys them to the U.S. after a planned terror attack linked to Iran was foiled

OilPrice.com

Fuel Price Shock Pushes Global Gas Car Sales Below 50% for First Time

NYT Business

P.&G.’s Chief on Whether Brand Loyalty Is Enough When Prices Keep Climbing

Business Insider